

Bio-Gene to present at NWR Virtual Healthcare Conference

Melbourne, Australia: Bio-Gene Technology Limited (ASX:BGT or ‘Bio-Gene’ or ‘the Company’), an Australian company developing the next generation of novel insecticides derived from nature, is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

CEO & Managing Director Tim Grogan will present at **1pm AEDT on Thursday 26 March 2026**.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

https://us02web.zoom.us/webinar/register/WN_5D15gAjkQcuC1F9jdOiuTQ

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company’s website and social media channels.

Questions can be submitted on the day or sent in advance to:

matt@nwrcommunications.com.au

For more information please visit: <https://nwrcommunications.com/healthconf>

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and demand for natural insecticides. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health, animal health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

www.bio-gene.com.au

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.
